Dublin, Sept. 24, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/czq5tp/companion)
has announced the addition of the "Companion
Diagnostics - Streamlining Drug Development and Advancing
Personalized Medicine" report to their offering.
Personalized healthcare encompasses tailored diagnostics, treatment
and management of illnesses and diseases. Although the concept has
been around for many years, it is only with the advent of companion
diagnostics that personalized healthcare has started to gain
ground. Companion diagnostics can be used in screening, monitoring,
diagnosing and treating patients and can allow for stratification
of patients to maximize efficacy and minimize risk
Companion diagnostics can allow for a specific patient population
to be identified which will ensure those patients who are most
likely to respond are recruited for clinical trials and receive the
therapy once the product is launched. Companion
diagnostics can help to rationalize treatment decisions, with
specifics such as accurate dosing, risks of adverse events and
diagnostics being made possible through these tests. Through the
use of companion diagnostics, the right treatment can be delivered
to the right patient at the right time, delivering greater value
and optimizing healthcare resource utilization
Oncology has been the most active arena for companion diagnostics
but, as research has advanced and new diagnostics developed,
applications in other therapy areas are being discovered and
established
The report, Companion Diagnostics - Streamlining Drug Development
and Advancing Personalized Medicine was written to support both the
biopharmaceutical and diagnostic industries better understand the
current challenges involved in developing products with a companion
diagnostic, as well as the opportunities that will exist in the
future. Recent success stories are identified and analyzed, and
insights are provided throughout the study to support
pharmaceutical & diagnostic strategic planning needs.
Key Reasons to Purchase
- This report provides an overview of advantages offered by
companion diagnostics from early clinical development through to
product launch and ongoing use in the patient population
- Understand what personalized medicine and companion diagnostics are and how these are expected to change the face of disease management
- Enables you to understand some of the key challenges faced during the development of companion diagnostics and recommendations on how to overcome them
- Provides an in-depth analysis of key case studies highlighting the successful application of companion diagnostics and how this has impacted company activities
- Gain insight into which pharmaceutical companies are leading
the way in the development and application of companion diagnostics
while assessing the key partnerships in place with diagnostics
companies driving this sector forward
Key Topics Covered:
1. Executive summary
2. Methodology
3. Personalized medicine and companion diagnostics
- Personalized medicine overview
- What are biomarkers?
- What are companion diagnostics?
4. Advantages of companion diagnostics
- A more targeted patient population
- Focused drug development
- Rationalized treatment decisions
- Pharmacoeconomic advantages
5. Challenges in the development of companion diagnostics
- Logistical challenges
- Strategic business challenges
- Financial risks
- Regulatory challenges
6. Case studies
- Roche - leading the way with companion diagnostics
- Biogen Idec - a diagnostic to mitigate risk
- Xalkori - a sign of things to come?
7. A look to the future
- Companion diagnostics - a prerequisite to approval?
- A world beyond oncology
- Companies leading the way
For more information visit http://www.researchandmarkets.com/research/czq5tp/companion
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Pharmaceuticals